OPKO Health and Entera Bio abstract selected for ESPEN Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
July 8, 2025 8:00 AM UTCMIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) and Entera Bio Ltd. (NASDAQ: ENTX) (Entera) today announced that their abstract First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, taking place September 1316, 2025, in Prague, Czech Republic.
Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome
Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time &... More
